

# 25th Multidisciplinary Management of Cancers: A Case-Based Approach

March 7-9, 2025



Presented by the *Association of Northern California Oncologists* in collaboration with the Stanford Cancer Institute, UC Davis Comprehensive Cancer Center, and the UCSF Helen Diller Family Comprehensive Cancer Center.

The opinions expressed in this publication are those of the participating faculty and not necessarily those of the *Association of Northern California Oncologists* (ANCO), its members, or any supporters of this meeting.

Copyright © 2025 *Association of Northern California Oncologists*.

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining written permission from the *Association of Northern California Oncologists*.

# 25<sup>th</sup> Multidisciplinary Management of Cancers: A Case-Based Approach

## Hyatt Regency Monterey

### March 7-9, 2025

#### Friday, March 7, 2025

7:30 am	<i>Registration and Continental Breakfast</i>	
8:25 am	<b>Welcome and Opening Remarks</b>	
8:30 am	<b>Breast Cancer Tumor Board Cases</b>	<b>Laura Huppert, MD, UCSF</b> <b>Kelsey Natsuhara, MD, UCSF Fellow</b> Michael Alvarado, MD, UCSF Mili Arora, MD, UC Davis Helen Chew, MD, UC Davis Allison Kurian, MD, Stanford Amy McMullen, MD, Central Coast Oncology & Hematology Cathy Park, MD, UCSF Candice Sauder, MD, UC Davis Kimberly Stone, MD, Stanford Melinda Telli, MD, Stanford
10:30 am	<i>Break</i>	
11:00 am	<b>Hematologic Malignancies Tumor Board Cases</b>	<b>Krishna Komanduri, MD, UCSF</b> <b>Mike Randall, MD, UCSF Fellow</b> Shagun Arora, MD, UCSF Michael Green, MD, TPMG Jarrod Holmes, MD, Providence David Iberri, MD, Stanford Brian Jonas, MD, UC Davis Tom Martin, MD, UCSF William Shomali, MD, Stanford Catherine Smith, MD, UCSF Francisco Socola, MD, UC Davis
12:30 pm	<i>Lunch</i>	
1:30 pm	<b>Melanoma Board Cases</b>	<b>Pauline Funchain, MD, Stanford</b> <b>Tabitha Ting, MD, Stanford Fellow</b> Ryenne Brown, MD, Stanford Robert Canter, MD, UC Davis Adil Daud, MD, UCSF Juraj Kavecansky, MD, TPMG Kevin Kim, MD, Sutter CA Pacific Medical Center Research Institute Amanda Kirane, MD, Stanford Tianhong Li, MD, UC Davis Susan Swetter, MD, Stanford Katy Tsai, MD, UCSF

3:00 pm	<i>Break</i>	
3:30 pm	<b>Supportive Oncology and Survivorship</b>	<b>Surbhi Singhal, MD, UC Davis</b> <b>Chloe Lalonde, MD, UC Davis Fellow</b> Ayana Davis, MD, UCSF Milana Dolezal, MD, Stanford Alex Fauer, MD, UC Davis Sara Keck, MD, Providence Angela Laffan, MD, UCSF Michael Rabow, MD, UCSF Kavitha Ramchandran, MD, Stanford Lidia Schapira, MD, Stanford Anjali Sibley, MD, Stanford
5:00 pm	<i>Daily Meeting Adjourns</i>	
5:00 -6:30 pm	<b>Welcome Reception</b>	

## Saturday, March 8, 2025

8:00 am	<i>Continental Breakfast</i>	
8:25 am	<b>Welcome and Opening Remarks</b>	
8:30 am	<b>Thoracic Cancer Tumor Board Cases</b>	<b>Jonathan Riess, MD, UC Davis</b> <b>Aneeqa Zafar, MD, UC Davis Fellow</b> Leah Backhus, MD, Stanford Deepti Behl, MD, Sutter Health Colin Blakely, MD, UCSF David Cooke, MD, UC Davis David Gandara, MD, UC Davis Johannes Kratz, MD, UCSF Ana Velazquez Manana, MD, UCSF Meera Ragavan, MD, TMPG Lucas Vitzthum, MD, Stanford Heather Wakelee, MD, Stanford
10:30 am	<i>Break</i>	
11:00 am	<b>Lymphoma Tumor Board Cases</b>	<b>Michael Khodadoust, MD, Stanford</b> <b>Navika Shukla, MD, Stanford Fellow</b> Sushma Bharadwaj, MD, Stanford Michael Binkley, MD, Stanford Erik Eckhert, MD, TPMG Naseem Esteghamat, MD, UC Davis Lisa Law, MD, TPMG Joe Schroers-Martin, MD, Stanford Mwanasha Merrill, MD, UCSF Michael Spinner, MD, UCSF Joseph Tuscano, MD, UC Davis
12:30 pm	<i>Lunch</i>	

1:30 pm	<b>CNS Tumor Board Cases</b>	<b>Jennie Taylor, MD, UCSF</b> <b>Thomas Nelson, MD, UCSF Junior Faculty</b> Orwa Aboud, MD, <i>UC Davis</i> Steve Braunstein, MD, <i>UCSF</i> Melanie Hayden Gephart, MD, <i>Stanford</i> Iris Catrice Gibbs, MD, <i>Stanford</i> Antonio Omuro, MD, <i>Stanford</i> Nancy Rubin, DO, <i>Pacific Cancer Care</i> Matt Susko, MD, <i>UCSF</i> Jacob Young, MD, <i>UCSF</i>
3:00 pm	<i>Daily Meeting Adjourns</i>	

## Sunday, March 9, 2025

8:00 am	<i>Continental Breakfast</i>	
8:25 am	<b>Welcome and Opening Remarks</b>	
8:30 am	<b>Gastrointestinal Cancers Tumor Board Cases</b>	<b>Lipika Goyal, MD, Stanford</b> <b>Pamela Basto, MD, Stanford Fellow</b> Karen Chee, MD, <i>UCSF</i> Steven Corsello, MD, <i>Stanford</i> Cameron Gaskill, MD, <i>UC Davis</i> Andrew Ko, MD, <i>UCSF</i> M. Zach Koontz, MD, <i>Pacific Cancer Care</i> Steve Lee, MD, <i>TPMG</i> Ajay Maker, MD, <i>UCSF</i> Erqi Liu Pollom, MD, <i>Stanford</i> Ankit Sarin, MD, <i>UC Davis</i> Brendan Visser, MD, <i>Stanford</i>
10:30 am	<i>Break</i>	
11:00 am	<b>Genitourinary Cancers Tumor Board Cases</b>	<b>Mamta Parikh, MD, UC Davis</b> <b>Aman Arora, MD, UC Davis Fellow</b> Hilary Bagshaw, MD, <i>Stanford</i> Thenappan Chandrasekar, MD, <i>UC Davis</i> Benjamin Chung, MD, <i>Stanford</i> Terence Friedlander, MD, <i>UCSF</i> Andrea Harzstark, MD, <i>TPMG</i> Ali Raza Khaki, MD, <i>Stanford</i> Richard Valicenti, MD, <i>UC Davis</i> Samuel Washington, MD, <i>UCSF</i> Anthony Wong, MD, <i>UCSF</i> Lulu Zhang, MD, <i>Pacific Cancer Care</i>
12:30 pm	<b>Adjourn</b>	

# 25th Multidisciplinary Management of Cancers: A Case-Based Approach

## **Program Overview**

The 25th Multidisciplinary Management of Cancers: A Case-Based Approach meeting will present the most current information on multidisciplinary approaches in clinical oncology and will consist of tumor board cases on breast cancer, CNS cancers, hematologic malignancies, genitourinary cancers, gastrointestinal cancers, lymphoma, melanoma, supportive oncology and survivorship, and thoracic cancer. The tumor board cases will be presented by faculty, with discussion by a panel of surgical, radiation, and medical oncologists from Stanford, UC Davis, UC San Francisco, The Permanente Medical Group, and the practice community.

### **Learning Objectives:**

- Develop multidisciplinary treatment strategies based on national clinical practice guidelines in oncology in order to improve quality of care for cancer patients.
- Discuss relevant clinical trials with cancer patients and refer appropriately.

## **Target Audience**

**Multidisciplinary Management of Cancers: A Case-Based Approach** has been designed to meet the educational needs of oncologists, oncology nurses, oncology pharmacists, and other health care professionals involved in the care of people with cancer.

## **Program Planning Committee**

The Physician Course Directors for **Multidisciplinary Management of Cancers: A Case-Based Approach** are:

**A. Dimitrios Colevas, MD,**  
*Stanford University School of Medicine*

**David Gandara, MD,**  
*University of California Davis Comprehensive Cancer Center*

**Margaret Tempero, MD,**  
*University of California, San Francisco*

## Accreditation Details



*Jointly provided by ANCO and i3 Health.*

### ACCREDITATION

In support of improving patient care, this activity has been planned and implemented by i3 Health and ANCO. i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

#### Physicians

i3 Health designates this live activity 15 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

#### Physician Assistants

Physician Assistants, American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for *AMA PRA Category 1 Credit*<sup>™</sup> from organizations accredited by ACCME. Physician assistants may receive a maximum of 15 hours of Category 1 credit for completing this program.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 15 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.

### INSTRUCTIONS TO RECEIVE CREDIT

An activity evaluation form will be distributed. To claim credit, you must fill out and submit the form at the conclusion of the program. Your certificate of attendance will either be mailed or emailed to you after your evaluations have been reviewed.

### UNAPPROVED USE DISCLOSURE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

### DISCLAIMER

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

## Meeting Faculty

### Course Directors

**A. Dimitrios Colevas, MD**

*Stanford University School of Medicine*

**David Gandara, MD**

*University of California Davis Comprehensive Cancer Center*

**Margaret Tempero, MD**

*University of California, San Francisco*

### Panel Chairs

**Pauline Funchain, MD**

*Stanford University*

**Melanoma Tumor Board Cases**

**Lipika Goyal, MD, PhD**

*Stanford University*

**Gastrointestinal Cancers Tumor Board Cases**

**Laura Huppert, MD**

*University of California, San Francisco*

**Breast Cancer Tumor Board Cases**

**Michael Khodadoust, MD, PhD**

*Stanford University*

**Lymphoma Tumor Board Cases**

**Krishna Komanduri, MD**

*University of California, San Francisco*

**Hematologic Malignancies Tumor Board Cases**

**Mamta Parikh, MD, MS**

*University of California, Davis*

**Genitourinary Cancers Tumor Board Cases**

**Jonathan Riess, MD, MS**

*University of California, Davis*

**Thoracic Cancer Tumor Board Cases**

**Surbhi Singhal, MD**  
*University of California, Davis*  
**Supportive Oncology and Survivorship**

**Jennie Taylor, MD, MPH**  
*University of California, San Francisco*  
**CNS Tumor Board Cases**

## Panelists

**Orwa Aboud, MD, PhD**  
*University of California, Davis*  
**CNS Tumor Board Cases**

**Michael Alvarado, MD**  
*University of California, San Francisco*  
**Breast Cancer Tumor Board Cases**

**Aman Arora, MD**  
*University of California, Davis*  
**Genitourinary Cancers Tumor Board Cases**

**Mili Arora, MD**  
*University of California, Davis*  
**Breast Cancer Tumor Board Cases**

**Shagun Arora, MD**  
*University of California, San Francisco*  
**Hematologic Malignancies Tumor Board Cases**

**Leah Backhus, MD**  
*Stanford University*  
**Thoracic Cancer Tumor Board Cases**

**Hilary Bagshaw**  
*Stanford University*  
**Genitourinary Cancers Tumor Board Cases**

**Pam Basto, MD, PhD**  
*Stanford University*  
**Gastrointestinal Cancers Tumor Board Cases**

**Deepti Behl, MD**  
*Sutter Health*  
**Thoracic Cancer Tumor Board Cases**



**Sushma Bharadwaj, MD, MS**  
*Stanford University*  
**Lymphoma Tumor Board Cases**

**Michael Binkley, MD, MS**  
*Stanford University*  
**Lymphoma Tumor Board Cases**

**Collin Blakely, MD, PhD**  
*University of California, San Francisco*  
**Thoracic Cancer Tumor Board Cases**

**Steve Braunstein, MD, PhD**  
*University of California, San Francisco*  
**CNS Tumor Board Cases**

**Ryanne Brown, MD, MBA**  
*Stanford University*  
**Melanoma Tumor Board Cases**

**Robert Canter, MD**  
*University of California, Davis*  
**Melanoma Tumor Board Cases**

**Iris Catrice Gibbs, BS, MD**  
*Stanford University*  
**CNS Tumor Board Cases**

**Thenappan Chandrasekar, MD**  
*University of California, Davis*  
**Genitourinary Cancers Tumor Board Cases**

**Karen Chee, MD**  
*University of California, San Francisco*  
**Gastrointestinal Cancers Tumor Board Cases**

**Helen Chew, MD**  
*University of California, Davis*  
**Breast Cancer Tumor Board Cases**

**Benjamin Chung, MD**  
*Stanford University*  
**Genitourinary Cancers Tumor Board Cases**

**David Cooke, MD**  
*University of California, Davis*  
**Thoracic Cancer Tumor Board Cases**

**Steven Corsello, MD**  
*Stanford University*  
**Gastrointestinal Cancers Tumor Board Cases**

**Adil Daud, MD**  
*University of California, San Francisco*  
**Melanoma Tumor Board Cases**

**Ayana Davis, MS, RD**  
*University of California, San Francisco*  
**Supportive Oncology and Survivorship**

**Milana Dolezal, MD, MSci**  
*Stanford University*  
**Supportive Oncology and Survivorship**

**Erik Eckhert, MD, MS**  
*The Permanente Medical Group*  
**Lymphoma Tumor Board Cases**

**Naseem Esteghamat, MD**  
*University of California, Davis*  
**Lymphoma Tumor Board Cases**

**Alex Fauer, MD, PhD**  
*University of California, Davis*  
**Supportive Oncology and Survivorship**

**Terence Friedlander, MD**  
*University of California, San Francisco*  
**Genitourinary Cancers Tumor Board Cases**

**Cameron Gaskill, MD, MPH**  
*University of California, Davis*  
**Gastrointestinal Cancers Tumor Board Cases**

**Michael Green, MD**  
*Hematologic Malignancies Tumor Board Cases*  
**The Permanente Medical Group**

**Andrea Harzstark, MD**  
*The Permanente Medical Group*  
**Genitourinary Cancers Tumor Board Cases**

**Melanie Hayden Gephart, MD, MAS**  
*Stanford University*  
**CNS Tumor Board Cases**

**Jarrold Holmes, MD, MAS**  
*Providence Medical Group*  
**Hematologic Malignancies Tumor Board Cases**

**David Iberri, MD**  
*Stanford University*  
**Hematologic Malignancies Tumor Board Cases**

**Brian Jonas, MD, PhD**  
*University of California, Davis*  
**Hematologic Malignancies Tumor Board Cases**

**Juraj Kavecansky, MD**  
*The Permanente Medical Group*  
**Melanoma Tumor Board Cases**

**Sara Keck, MD**  
*Providence Medical Group*  
**Supportive Oncology and Survivorship**

**Ali Khaki, MD**  
*Stanford University*  
**Genitourinary Cancers Tumor Board Cases**

**Kevin Kim, MD**  
*Sutter California Pacific Medical Center Research Institute*  
**Breast Cancer Tumor Board Cases**

**Amanda Kirane, MD, PhD**  
*Stanford University*  
**Melanoma Tumor Board Cases**

**Andrew Ko, MD**  
*University of California, San Francisco*  
**Gastrointestinal Cancers Tumor Board Cases**

**M. Zach Koontz, MD**  
*Pacific Cancer Care*  
**Gastrointestinal Cancers Tumor Board Cases**

**Johannes Kratz, MD**  
*University of California, San Francisco*  
**Thoracic Cancer Tumor Board Cases**

**Allison Kurian, MD, MSc**  
*Stanford University*  
**Breast Cancer Tumor Board Cases**

**Angela Laffan, MS**

*University of California, San Francisco*

**Supportive Oncology and Survivorship**

**Chloe Lalonde, MD**

*University of California, Davis*

**Supportive Oncology and Survivorship**

**Lisa Law, MD**

*The Permanente Medical Group*

**Lymphoma Tumor Board Cases**

**Steve Lee, MD**

*The Permanente Medical Group*

**Gastrointestinal Cancers Tumor Board Cases**

**Tianhong Li, MD, PhD**

*University of California, Davis*

**Melanoma Tumor Board Cases**

**Ajay Maker, MD**

*University of California, San Francisco*

**Gastrointestinal Cancers Tumor Board Cases**

**Ana Velazquez Manana, MD, MSc**

*University of California, San Francisco*

**Thoracic Cancer Tumor Board Cases**

**Tom Martin, MD**

*University of California, San Francisco*

**Hematologic Malignancies Tumor Board Cases**

**Amy McMullen, MD**

*Central Coast Oncology and Hematology*

**Breast Cancer Tumor Board Cases**

**Mwanasha Merrill, MD**

*University of California, San Francisco*

**Lymphoma Tumor Board Cases**

**Kelsey Natsuhara, MD**

*University of California, San Francisco*

**Breast Cancer Tumor Board Cases**

**Thomas Nelson, MD**

*University of California, San Francisco*

**CNS Tumor Board Cases**

**Antonio Omuro, MD**  
*Stanford University*  
**CNS Tumor Board Cases**

**Catherine Park, MD**  
*University of California, San Francisco*  
**Breast Cancer Tumor Board Cases**

**Erqi Liu Pollom, MD**  
*Stanford University*  
**Gastrointestinal Cancers Tumor Board Cases**

**Michael Rabow, MD**  
*University of California, San Francisco*  
**Supportive Oncology and Survivorship**

**Meera Ragavan, MD, MPH**  
*The Permanente Medical Group*  
**Thoracic Cancer Tumor Board Cases**

**Kavitha Ramchandran, MD**  
*Stanford University*  
**Supportive Oncology and Survivorship**

**Michael Randall, md**  
*University of California, San Francisco*  
**Hematologic Malignancies Tumor Board Cases**

**Nancy Rubin, DO**  
*Pacific Cancer Care*  
**CNS Tumor Board Cases**

**Ankit Sarin, MD, MHA**  
*University of California, Davis*  
**Gastrointestinal Cancers Tumor Board Cases**

**Candice Sauder, MD, MEd**  
*University of California, Davis*  
**Breast Cancer Tumor Board Cases**

**Lidia Schapira, MD**  
*Stanford University*  
**Supportive Oncology and Survivorship**

**Joe Schroers-Martin, MD**  
*Stanford University*  
**Lymphoma Tumor Board Cases**

**William Shomali, MD**  
*Stanford University*  
**Hematologic Malignancies Tumor Board Cases**

**Navika Shukla, MD**  
*Stanford University*  
**Lymphoma Tumor Board Cases**

**Anjali Sibley, MD, MPH**  
*Stanford University*  
**Supportive Oncology and Survivorship**

**Catherine Smith, MD**  
*University of California, San Francisco*  
**Hematologic Malignancies Tumor Board Cases**

**Francisco Socola, MD**  
*University of California, Davis*  
**Hematologic Malignancies Tumor Board Cases**

**Michael Spinner, MD**  
*University of California, San Francisco*  
**Lymphoma Tumor Board Cases**

**Kimberly Stone, MD**  
*Stanford University*  
**Breast Cancer Tumor Board Cases**

**Matt Susko, MD, MS**  
*University of California, San Francisco*  
**CNS Tumor Board Cases**

**Susan Swetter, MD**  
*Stanford University*  
**Melanoma Tumor Board Cases**

**Melinda Telli, MD**  
*Stanford University*  
**Breast Cancer Tumor Board Cases**

**Tabitha Ting, MD, PhD**  
*Stanford University*  
**Melanoma Tumor Board Cases**

**Katy Tsai, MD**  
*University of California, San Francisco*  
**Melanoma Tumor Board Cases**

**Joseph Tuscano, MD**  
University of California, Davis  
**Lymphoma Tumor Board Cases**

**Richard Valicenti, MD**  
*University of California, Davis*  
**Genitourinary Cancers Tumor Board Cases**

**Brendan Visser, MD**  
*Stanford University*  
**Gastrointestinal Cancers Tumor Board Cases**

**Lucas Vitzthum, MD, MAS**  
*Stanford University*  
**Thoracic Cancer Tumor Board Cases**

**Heather Wakelee, MD, FASCO**  
*Stanford University*  
**Thoracic Cancer Tumor Board Cases**

**Samuel Washington, MD, MAS**  
*University of California, San Francisco*  
**Genitourinary Cancers Tumor Board Cases**

**Anthony Wong, MD**  
*University of California, San Francisco*  
**Genitourinary Cancers Tumor Board Cases**

**Jacob Young, MD**  
*University of California, San Francisco*  
**CNS Tumor Board Cases**

**Aneeqa Zafar, MD**  
*University of California, Davis*  
**Thoracic Cancer Tumor Board Cases**

**Lulu Zhang, MD, MPH**  
*Pacific Cancer Care*  
**Genitourinary Cancers Tumor Board Cases**

## Speaker Disclosure of Relevant Financial Relationships

*Relevant financial relationships for all planners, reviewers, and faculty have been mitigated.*

### **Orwa Aboud, MD**

Disclosed the following financial relationships; **Advisory Board or Panel:** Servier Pharmacology;  
**Consultant:** MRI math, Adivo Association, General Dynamics, Woltera Kluwer, and Sago.

### **Michael Alvarado, MD**

Disclosed no relevant financial relationships.

### **Aman Arora, MD**

Disclosed no relevant financial relationships.

### **Mili Arora, MD**

Disclosed no relevant financial relationships.

### **Shagun Arora, MD**

Disclosed no relevant financial relationships.

### **Leah Backhus, MD**

Disclosed the following financial relationships; **Advisory Board or Panel:** Johnson & Johnson, AstraZeneca, and Genentech; **Grants/Research Support:** Department of Veterans Affairs and NIH.

### **Hilary Bagshaw, MD**

Disclosed no relevant financial relationships.

### **Pam Basto, MD**

Disclosed no relevant financial relationships. **Disclosed Patents** - Cartesian Therapeutics, Stem Cell Technologies.

### **Deepti Behl, MD**

Disclosed the following financial relationships; **Advisory Board or Panel:** BMS, Boehringer, Janssen and Janssen, and Caris.

### **Sushma Bharadwaj, MD**

Disclosed no relevant financial relationships. Disclosed **Grants/Research Support:** Allogene.

### **Michael Binkley, MD**

Disclosed no relevant financial relationships.

### **Collin Blakely, MD**

Disclosed the following financial relationships; **Advisory Board or Panel:** Gilead, Bayer, BMS, Takeda, Pfizer, Janssen, and Taiho; **Grants/Research Support:** AstraZeneca, Genentech, Mirati, Puma, and Novartis.



**Steve Braunstein, MD**

Disclosed no relevant financial relationships.

**Ryanne Brown, MD**

Disclosed no relevant financial relationships.

**Robert Canter, MD**

Disclosed the following financial relationships; **Advisory Board or Panel:** Replimune;  
**Stock/Shareholder (excluding diversified mutual funds):** Abbvie Inc Com, Abbott Labs Com  
Astrazeneca Plc Sponsored Adr, Bristol-Myers Squibb Co Com, Johnson & Johnson Com, and Pfizer Inc  
Com.

**Iris Catrice Gibbs, MD**

Disclosed no relevant financial relationships.

**Thenappan Chandrasekar, MD**

Disclosed no relevant financial relationships.

**Karen Chee, MD**

Disclosed no relevant financial relationships.

**Helen Chew, MD**

Disclosed no relevant financial relationships.

**Benjamin Chung, MD**

Disclosed the following financial relationships; **Consultant:** Intuitive Surgical, Johnson and Johnson, and  
Medtronic; **Salary/Contractual Services:** VPIX Incorporated and DeepQure.

**Dimitrios Colevas, MD**

Disclosed the following financial relationships; **Advisory Board or Panel:** PDS biotech DSMB 2024, aveo  
DSMB 2024, inhibrix consulting 2023; **Grants/Research Support:** National Institutes of Health  
02/01/2019-01/31/2025 clinical trial support, Cue Biopharma, Inc. 01/15/2020-06/30/2025 clinical trial  
support, Replimune Inc./Replimune Inc. 11/30/2020-08/31/2026 clinical trial support, BioNTech  
06/07/2021-06/30/2026 clinical trial support, Gilead Sciences 08/30/2021-08/30/2025 clinical trial  
support, Viracta Therapeutics, Inc. 03/07/2022-03/15/2026 clinical trial support, Foundation of the  
American Society of Neuroradiology 07/01/2023-06/30/2025 clinical research funding, Cofactor  
Genomics 05/08/2023-04/30/2025 clinical research funding, and Regeneron Pharmaceuticals  
Inc./Regeneron Pharmaceuticals, Inc. 10/19/2023-10/31.

**David Cooke, MD**

Disclosed the following financial relationships; **Speaker's Bureau:** Bristol Myers Squibb - Speaker  
Honoraria; **Grants/Research Support:** Intuitive Surgical - In kind education support; **Other Financial or  
Material Support (royal@es, patents, etc.):** Oxford University Press - Royalties.

**Steven Corsello, MD**

Disclosed the following financial relationships; **Grants/Research Support:** Past lab research funding from Bayer and Calico; **Other Financial or Material Support (royal@es, patents, etc.):** Past lecture honorarium from Genentech.

**Adil Daud, MD**

Disclosed the following financial relationships; **Advisory Board or Panel:** Genoptix; GlaxoSmithKline; Caris, Eisai, and GLG; **Consultant:** Genoptix, GlaxoSmithKline, Oncosec, Caris, Eisai, and GLG; **Grants/Research Support:** Bristol-Myers Squibb; Checkmate Pharmaceuticals; Checkmate Pharmaceuticals; Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte; Merck/Schering; **Stock/Shareholder (excluding diversified mutual funds):** Neuvogen; Trex bio.

**Ayana Davis, MD**

Disclosed no relevant financial relationships.

**Milana Dolezal, MD**

Disclosed the following financial relationships; **Advisory Board or Panel:** AstraZeneca (once in 2024), Gilead (once in 2025).

**Erik Eckhert, MD**

Disclosed no relevant financial relationships.

**Naseem Esteghamat, MD**

Disclosed no relevant financial relationships.

**Alex Fauer, MD**

Disclosed no relevant financial relationships.

**Terence Friedlander, MD**

Disclosed the following financial relationships; **Advisory Board or Panel:** Aadi Biosciences, Abbvie, Adaptimmune, Astellas, Atkis Oncology, Bicycle Therapeutics, Bristol Meyers Squibb, Gilead, Merck Sharp & Dohme, McKesson, Pfizer/Seagen, and Samsung Bioepis; **Consultant:** Samsung Bioepis; **Grants/Research Support:** Roche Genentech, Pfizer, J&J Innovative Medicine, and Bicycle Therapeutics.

**Pauline Funchain, MD**

Disclosed the following financial relationships; **Consultant:** BMS, Merck, GigaGen, Eisai, Novartis, Array, Hexal AG, Replimune, Immunocore and Sanofi; **Grants/Research Support:** Dr. Funchain reports research grants to her current and former institutions from Ideaya, BMS, Pfizer and Taiho Oncology

**David Gandara, MD**

Disclosed the following financial relationships; **Advisory Board or Panel:** Mirati Therapeutics and Regeneron; **Consultant:** AstraZeneca, Exact Sciences, Genentech, Guardant Health, Henlius USA, and Foundation Medicine; **Grants/Research Support:** Astex Pharma, Amgen Inc., and Genentech.

**Cameron Gaskill, MD**

Disclosed no relevant financial relationships.

**Lipika Goyal, MD**

Disclosed the following financial relationships; **Advisory Board or Panel:** AbbVie, Agenus, AstraZeneca (DSMB), Boehringer Ingelheim, Compass Therapeutics, Exelixis, Kinnate Biopharma, Merck, Relay Therapeutics, Servier, Surface Oncology, Taiho, and TransThera; **Grants/Research Support:** Alyssum Therapeutics, Boehringer Ingelheim, Genentech, AstraZeneca, Cogent, and Tyra Biosciences.

**Michael Green, MD**

Disclosed no relevant financial relationships.

**Andrea Harzstark, MD**

Disclosed no relevant financial relationships.

**Melanie Hayden Gephart, MD**

Disclosed the following financial relationships; **Advisory Board or Panel:** SensoBrain and Telix; **Grants/Research Support:** Quadriga; **Stock/Shareholder (excluding diversified mutual funds):** SmartLens.

**Jarrod Holmes, MD**

Disclosed the following financial relationships; **Speaker's Bureau:** Pharmacyclics and Glaxo Smith Kline.

**Laura Huppert, MD**

Disclosed the following financial relationships; **Advisory Board or Panel:** AstraZeneca and Pfizer; **Grants/Research Support:** Greenwich LifeSciences.

**David Iberri, MD**

Disclosed no relevant financial relationships.

**Brian Jonas, MD**

Disclosed the following financial relationships; **Advisory Board or Panel:** AbbVie, Kura, Rigel, Schrodinger, Syndax, and Treadwell; **Consultant:** AbbVie, BMS, Gilead, Kura, Rigel, Schrodinger, Syndax, and Treadwell; **Grants/Research Support:** Research funding to my institution from AbbVie, Amgen, Aptose, AROG, Biomea, BMS, Celgene, Forma, Forty-Seven, Genentech/Roche, Gilead, GlycoMimetics, Hanmi, Immune-Onc, Jazz, Kymera, Loxo, Pfizer, Pharmacyclics, and Treadwell; **Other Financial or Material Support (royalties, patents, etc.):** Travel reimbursement/support from Rigel; Data monitoring committee for Gilead.

**Juraj Kavecansky, MD**

Disclosed no relevant financial relationships.

**Sara Keck, MD**

Disclosed no relevant financial relationships.

**Ali Khaki, MD**

Disclosed the following financial relationships; **Advisory Board or Panel:** Pfizer (declined remuneration); **Consultant:** Janssen (declined remuneration); **Grants/Research Support:** 23andMe, Pfizer, Janssen, Acrivon Therapeutics.

**Michael Khodadoust, MD**

Disclosed the following financial relationships; **Consultant:** Ono Pharma and Ephla Bio; **Grants/Research Support:** Ono Pharma and Nutcracker Bio.

**Kevin Kim, MD**

Disclosed the following financial relationships; **Advisory Board or Panel:** BMS, Merck Eisai, Regeneron, and Pfizer; **Speaker's Bureau:** Bristol Myer Squibbs; **Grants/Research Support:** Bristol Myer Squibbs,, Merck, ImmunoCore, lovance, Moderna, Ideaya, Regeneron, Summit, and Replimmune.

**Amanda Kirane, MD**

Disclosed the following financial relationships; **Consultant:** Expert speaker/ panelist for lovance- February, March 2024 and Surgical consultant - replimmune August 2024, lovance October 2024.

**Andrew Ko, MD**

Disclosed the following financial relationships; **Advisory Board or Panel:** (One-time advisory boards) Arcus, Astellas, Corcept Therapeutics, Eisai, Fibrogen, Lenovo, Merus, Renovo, and Tango Therapeutics; **Grants/Research Support:** (for support of clinical trials, paid directly to my institution) Abgenomics, Apexigen/Pyxis, Astellas, Biomedical Valley Discoveries, Bristol-Myers Squibb, Genentech/Roche, LEAP Therapeutics, and Verastem; **Salary/Contractual Services:** (Member of Independent Data Monitoring Committees) Roche/Genentech, Ipsen, and Grail.

**Krishna Komanduri, MD**

Disclosed the following financial relationships; **Advisory Board or Panel:** Scientific Advisory Board - Aegle Therapeutics, CellChorus, Clinical Advisory Board - Optum Health; **Consultant:** Ad hoc Consulting- lovance, Incyte, Cargo Therapeutics, CRISPR therapeutics, Genentech/Roche, and BMS.

**M. Zach Koontz, MD**

Disclosed the following financial relationships; **Stock/Shareholder (excluding diversified mutual funds):** Merck <\$50k

**Johannes Kratz, MD**

Disclosed the following financial relationships; **Advisory Board or Panel:** Intuitive Surgical ION Medical Advisory Board; **Speaker's Bureau:** Razor Genomics; **Consultant:** Razor Genomics and Intuitive Surgical.

**Allison Kurian, MD**

Disclosed the following financial relationships; **Grants/Research Support:** Research support for an investigator-initiated study to my institution from Myriad Genetics, 2017-2019.

**Angela Laffan, MD**

Disclosed no relevant financial relationships.

**Chloe Lalonde, MD**

Disclosed no relevant financial relationships.

**Lisa Law, MD**

Disclosed no relevant financial relationships.

**Steven Lee, MD**

Disclosed no relevant financial relationships.

**Tianhong Li, MD**

Disclosed the following financial relationships; **Advisory Board or Panel:** Bristol Myers Squibb (BMS); **Grants/Research Support:** AbbVie, Amgen, Astellas, AstraZeneca, Bristol Myers Squibb (BMS), Chugai Pharma, Duality Biologics, Genentech/LaRoche, Jounce Therapeutics, LabyRx, Immuno-Oncology, Merck, OncoC4/BioNTech, Novartis, RasCal Therapeutics, Tempus, and Xilio Therapeutics.

**Ajay Maker, MD**

Disclosed no relevant financial relationships. Disclosed **Grants/Research Support:** Shannon Biosciences.

**Ana Velazquez Manana, MD**

Disclosed the following financial relationships; **Advisory Board or Panel:** AbbVie, AstraZeneca Pharmaceuticals, Janssen, Merus NV, Novocure, and Regeneron; **Other Financial or Material Support (royal@es, patents, etc.):** Merck and Pfizer.

**Tom Martin, MD**

Disclosed the following financial relationships; **Consultant:** GSK, Pfizer, Lilly; **Grants/Research Support:** Sanofi, AMGEN, BMS, and Janssen.

**Amy McMullen, MD**

Disclosed no relevant financial relationships.

**Mwanasha Merrill, MD**

Disclosed no relevant financial relationships.

**Kelsey Natsuhara, MD**

Disclosed no relevant financial relationships.

**Thomas Nelson, MD**

Disclosed no relevant financial relationships.

**Antonio Omuro, MD**

Disclosed the following financial relationships; **Advisory Board or Panel:** Ono Pharma, Nurix, Telix, Servier, and Curevac; **Grants/Research Support:** Arcus Biosciences.

**Mamta Parikh, MD**

Disclosed the following financial relationships; **Advisory Board or Panel:** Bicycle Therapeutics, Exelixis, Pfizer, Bristol Myers Squibb, Sanofi Aventis; **Consultant:** Totus Medicines; **Grants/Research Support:** Gilead and Karyopharm.

**Catherine Park, MD**

Disclosed no relevant financial relationships.

**Erqi Liu Pollom, MD**

Disclosed the following financial relationships; **Advisory Board or Panel:** Vysioneer, GT Medical Technologies, and Castle Biosciences; **Speaker's Bureau:** Varian; **Salary/Contractual Services:** Stanford.

**Mike Rabow, MD**

Disclosed no relevant financial relationships.

**Meera Ragavan, MD**

Disclosed the following financial relationships; **Consultant:** Trial Library, Inc.; **Grants/Research Support:** Community Benefit Program and The Permanente Medical Group.

**Kavitha Ramchandran, MD**

Disclosed no relevant financial relationships.

**Mike Randall, MD**

Disclosed no relevant financial relationships

**Jonathan Riess, MD**

Disclosed the following financial relationships; **Advisory Board or Panel:** Advisory Board with honoraria paid to individual - BMS, Janssen, Genentech, Regeneron, Merus NV, Catalyst, Amgen, Oncohost, Merck, Pfizer, GSK, Daichi Sankyo, and Replimune; **Consultant:** Consulting with honoraria paid to individual - BMS, Janssen, Genentech, Regeneron, Merus NV, Catalyst, Amgen, Oncohost, Merck, Pfizer, GSK, Daichi Sankyo, and Replimune; **Grants/Research Support:** Research funding paid to institution - Pfizer, Boehringer Ingelheim, Revolution Medicines, ArriVent, Nuvalent, Kinnate, IO Biotech, AstraZeneca, Merck, Novartis, and Summit.

**Nancy Rubin, MD**

Disclosed no relevant financial relationships.

**Ankit Sarin, MD**

Disclosed the following financial relationships; **Consultant:** Noah Medical, Avert medical, and Intuitive Surgical.

**Candice Sauder, MD**

Disclosed no relevant financial relationships.

**Lidia Schapira, MD**

Disclosed no relevant financial relationships.

**Joe Schroers-Martin, MD**

Disclosed the following financial relationships; **Consultant:** Pierre Fabre Pharmaceuticals; **Other Financial or Material Support (royalties, patents, etc.):** Travel - Genentech and Beigene.

**William Shomali, MD**

Disclosed the following financial relationships; **Advisory Board or Panel:** Blueprint Medicines; **Consultant:** Incyte; **Grants/Research Support:** Incyte and Blueprint Medicines.

**Navika Shukla, MD**

Disclosed no relevant financial relationships.

**Anjali Sibley, MD**

Disclosed no relevant financial relationships. Disclosed Grants/Research Support: Stanford Cancer Institute.

**Surbhi Singhal, MD**

Disclosed the following financial relationships; **Advisory Board or Panel:** Caris and Oncohost.

**Catherine Smith, MD**

Disclosed the following financial relationships; **Advisory Board or Panel:** Biomea, Abbvie, and Genentech; **Grants/Research Support:** Erasca, Abbvie, Zentalis, and Biomea.

**Francisco Socola, MD**

Disclosed no relevant financial relationships.

**Michael Spinner, MD**

Disclosed the following financial relationships; **Advisory Board or Panel:** ADC Therapeutics; **Consultant:** Gilead/Kite; **Grants/Research Support:** Foresight Diagnostics, Seattle Genetics/Pfizer, and Allogene.

**Kimberly Stone, MD**

Advisory role for Petal Surgical and Always Health - no financial relationship

**Matt Susko, MD**

Disclosed no relevant financial relationships.

**Susan Swetter, MD**

Disclosed no relevant financial relationships.

**Jennie Taylor, MD**

Disclosed the following financial relationships; **Advisory Board or Panel:** Servier; **Consultant:** Mount Sinai Health Systems, University of Colorado and Curio Science; **Grants/Research Support:** Servier and BMS; **Other Financial or Material Support (royalties, patents, etc.):** UpToDate.

**Melinda Telli, MD**

**Advisory Board or Panel:** Astra Zeneca, Arivinas, Blueprint Medicines, Daiichi Sankyo, Foresight Diagnostics, Genentech, GSK, Merck, Natera, Novartis, Pfizer; **Consultant:** DSMC: G1 Therapeutics, Gilead; **Grants/Research Support:** Astra Zeneca, Arivinas, Blueprint Medicines, Genentech, GSK, Hummingbird Bioscience, Merck, OncoSec Medical, Pfizer.

**Margaret Tempero, MD**

Disclosed the following financial relationships; **Advisory Board or Panel:** AstraZeneca, BeiGene, Bristol Myers Squibb, ElmediX, Geron Corporation, Global Bio Access fund, Guardant Health, Immodulon Therapeutics Ltd, IPSEN Biopharma, Inc., Merus, Mirati Therapeutics Inc., PEPTOMYC, S.L., Regeneron, and RenovRx; **Consultant:** Astellas Pharma Global Development Inc.

**Tabitha Ting, MD**

Disclosed no relevant financial relationships.

**Katy Tsai, MD**

Disclosed the following financial relationships; **Advisory Board or Panel:** BMS; **Grants/Research Support:** Institutional research support: ABM Therapeutics, AstraZeneca, BioAtla, BMS, Genentech, Georgiamune, Ideaya Biosciences, Innovent, Oncosec, OnKure, Pfizer, Regeneron, and Replimune.

**Joseph Tuscano, MD**

Disclosed the following financial relationships; **Grants/Research Support:** ADC therapeutics, Genentech, Pharmacyclics, Abbvie, Genmab, Regeneron, Pfizer.

**Richard Valicenti, MD**

Disclosed no relevant financial relationships.

**Brendan Visser, MD**

Disclosed no relevant financial relationships.

**Lucas Vitzthum, MD**

Disclosed no relevant financial relationships.

**Heather Wakelee, MD**

Disclosed the following financial relationships; **Advisory Board or Panel:** IOBiotech (Sept 2023/Sept 2024), Mirati (ended Dec 2022), OncoC4 (4/2024 ongoing), Beigene (April 2024), and GSK (Sept 2024); **Speaker's Bureau:** None - paid by Chugai to provide CME lectures I developed (Nov 2024); **Consultant:** UNPAID Consultant Work: BMS (Oct 2023), Genentech/Roche ongoing; Merck ongoing; AstraZeneca ongoing; **Grants/Research Support:** AstraZeneca, Bayer, BMS, Genentech/Roche, Helsinn, Merck, SeaGen, and Xcovery; **Salary/Contractual Services:** Stanford University.

**Samuel Washington, MD**

Disclosed no relevant financial relationships.



**Jacob Young, MD**

Disclosed no relevant financial relationships.

**Aneeqa Zafar, MD**

Disclosed no relevant financial relationships.

**Lulu Zhang, MD**

Disclosed no relevant financial relationships.

## **Acknowledgement of Support**

This activity has been supported in part by:

### **Sustaining Plus Corporate Members**

AbbVie  
Amgen  
AstraZeneca  
BeiGene USA, Inc.  
Bristol-Meyers Squibb Oncology  
Daiichi Sankyo, Inc.  
Genmab  
Gilead Sciences, Inc.  
GSK Oncology  
Jazz Pharmaceuticals  
Johnson & Johnson  
Kite, A Gilead Company  
Merck & Co., Inc.  
Pfizer Oncology  
Regeneron  
Stemline, A Menarini Group Company  
Syndax Pharmaceuticals, Inc.

### **Premium Supporters**

Bayer  
Boehringer Ingelheim  
Incyte Corporation  
Novartis Pharmaceuticals  
Pharmacosmos Therapeutics, Inc.  
PharmaEssentia USA Corporation  
Sumitomo Pharma  
Takeda Oncology

## **Supporters**

Agios Pharmaceuticals  
ADC Therapeutics  
Astellas Pharma US  
Aveo Oncology, an LG Chem Company  
Caris Life Sciences  
Castle Biosciences  
Coherus  
Deciphera  
Eisai, Inc.  
EMD Serono  
Exact Sciences  
Exelixis, Inc.  
Genentech, a Member of the Roche Group  
Guardant Health  
Immunocore  
Ipsen  
Puma Biotechnology, Inc.  
Sanofi  
Servier Pharmaceuticals  
Sobi, Inc.  
SpringWorks Therapeutics  
Sun Pharma  
Taiho Oncology Inc.